Dear Renukaprasad A R, | This week, we bring you the most informative webinars on improving telemedicine practice, insights on osteoporosis, the role of robotics in kidney cancer surgery, and much more. Join the leading experts to discuss the latest topics in the field of medicine! | | | | Osteoporosis – A Global Epidemic? | Osteoporosis is a disease that can lead to compromised bone strength and a higher risk of fractures. It is mainly characterized by low bone mass, bone tissue degradation, and microarchitecture disorganization. Join the eminent Orthopedic Surgeon in our exclusive session, on 2nd October 2023, 3:00 PM IST onwards. | | | Telemedicine Practice | Cardiology-related Trials of 2022 | Over the years, the use of telemedicine has increased exponentially, with a fundamental aim to improve access to healthcare, even in remote areas.
In 2022, multiple cardiology-related clinical trials were successfully conducted. The findings of these trials have the potential to influence the current practice and future guidelines in cardiology.
To learn more, join our experts in an exclusive session organized in association with CIMS on 2nd October 2023, 6:00 PM IST. | | | | | Unleashing the Potential of Antimicrobial Stewardship | Efforts to address the growing problem of antimicrobial resistance (AMR) have been gaining momentum. However, most strategies for responsible antimicrobial use, such as Antimicrobial Stewardship or AMS, are typically implemented within individual healthcare organizations or specific sectors, which has led to limited progress in tackling this issue. Establishing a comprehensive, interdisciplinary strategy is essential to improve our approach.
To learn more about this topic, you can watch an interactive session organized by Pfizer bioMérieux and Docplexus. | | | Docplexus Online Services Pvt. Ltd. A-302, Teerth Technospace, Mumbai-Bengaluru Highway, Baner, Pune-411045, India. If you have any questions, feel free message us at support@mailus.com. All right reserved. Update email preferences or Unsubscribe. | | | |
No comments:
Post a Comment